The trypanosomatids are generally aberrant in their protein N-glycosylation pathways. However, protein Nglycosylation in the African trypanosome Trypanosoma brucei, aetiological agent of human African sleeping sickness, is not well understood. Here, we describe the creation of a bloodstream form T.brucei mutant that is deficient in the endoplasmic reticulum enzyme glucosidase II. Characterisation of the variant surface glycoprotein, the main glycoprotein synthesised by the parasite with two N-glycosylation sites, revealed unexpected changes in the N-glycosylation of this molecule. Structural characterisation by mass spectrometry, nuclear magnetic resonance spectroscopy and chemical and enzymatic treatments, revealed that one of the two glycosylation sites was occupied by conventional oligomannose structures while the other accumulated unusual structures in the form of Glcα1-3Manα1-2Manα1-2Manα1-3(Manα1-6)Manβ1-4GlcNAcβ1-4GlcNAc, Glcα1-3Manα 1-2Manα1-2Manα1-3(GlcNAcβ1-2Manα1-6)Manβ1-4GlcNAcβ1-4GlcNAc and Glcα1-3Manα1-2Manα 1-2Manα1-3(Galβ1-4GlcNAcβ1-2Manα1-6)Manβ1-4GlcNAcβ1-4GlcNAc. The possibility that these structures might arise from Glc 1 Man 9 GlcNAc 2 by unusually rapid α-mannosidase processing was ruled out using a cocktail of α-mannosidase inhibitors. The results suggest that bloodstream form T.brucei can transfer both Man 9 GlcNAc 2 and Man 5 GlcNAc 2 to the variant surface glycoprotein in a site-specific manner and that, unlike organisms that transfer exclusively Glc 3 Man 9 GlcNAc 2 , the T.brucei UDP-Glc:glycoprotein glucosyltransferase and glucosidase II enzymes can use Man 5 GlcNAc 2 and Glc 1 Man 5 GlcNAc 2 , respectively, as their substrates. The ability to transfer Man 5 GlcNAc 2 structures to Nglycosylation sites destined to become Man 4-3 GlcNAc 2 or complex structures may have evolved as a mechanism to conserve dolichol-phosphate-mannose donors for GPI anchor biosynthesis and points to fundamental differences in the specificities of host and parasite glycosyltransferases that initiate the synthesis of complex N-glycans.
During the bloodstream stage of the life cycle, the cells are covered in a densely packed coat of variant surface glycoprotein (VSG) 1 . The VSG coat serves as a physical barrier to components of the host complement system and undergoes antigenic variation (1) . There are many VSG genes, and each encodes a GPI anchored glycoprotein with one to three N-glycosylation sites (2, 3) . The cell line used in this study expresses VSG variant 221 (also known as MiTat1.2). VSG221 carries two occupied N-glycosylation sites, the glycan structures at which have been fully characterised (4) . The Asn428 site, five residues from the GPI attachment site, is occupied mostly by oligomannose structures (Man 7-9 GlcNAc 2 ), whilst the Asn263 site is occupied by small biantennary structures ranging from Man 3 GlcNac 2 to Gal 2 GlcNAc 2 Man 3 GlcNAc 2 .
Protein N-glycosylation serves a wide variety of functions including signalling through interaction with lectins, protein stabilization, protease resistance, endocytic sorting functions and protein folding (5) (6) (7) . In eukaryotes, the precursor for N-glycans is built up on the lipid carrier dolichol (Dol) located in the endoplasmic reticulum (ER) membrane. In most organisms, the final precursor is Glc 3 Man 9 GlcNAc 2 -PP-Dol, the glycan portion of which is transferred en bloc, via the action of oligosaccharyltransferase (OST), to Asn residues within Asn-X-Ser/Thr sequons during protein translation and sequestration into the lumen of the ER. Processing of the precursor structure by glycosidase and glycosyltransferase enzymes within the ER and Golgi apparatus generates the final set of mature structures. In the first steps of processing, the outer α1-2 linked glucose is removed by glucosidase I and the two remaining α1-3 linked glucose residues are removed by glucosidase II. Glucosidase II is a heterodimer; the catalytic α-subunit is a member of the family 31 glycosyl hydrolases and the β subunit generally contains a KDEL-type ER retention motif (8, 9) . The monoglucosylated Glc 1 Man 9 GlcNAc 2 structure resulting from removal of the outer two glucose residues allows newly synthesised glycoproteins to interact with the lectin like 'quality-control' chaperones calnexin and calreticulin (7, 10, 11) . The monoglucosylated structure can also be generated by the re-glucosylation of Man GlcNAc 2 structures by UDP-glucose: glycoprotein glucosyl transferase (UGGT), an enzyme that recognises proteins that are not fully folded (12) . Consistent with a role in folding for the monoglucosylated oligosaccharide structures, UGGT shows substrate preference for Man 9-7 GlcNAc 2 -containing glycans attached to denatured proteins in vitro (13) .
The seminal work of Parodi and colleagues has shown that protein N-glycosylation in several trypanosomatid parasites is aberrant, reviewed in (14) . None of these organisms can make Dol-P-Glc and so fail to make glucosylated Dol-PPoligosaccharide precursors. The mature Dol-PPoligosaccharide species used for transfer to protein vary according to trypanosomatid species. For example, Trypanosoma conhorini, T.dionisii, Leptomonas samueli, Herpetomonas samuelpessoai, and H.muscarum utilise triantennary Man 9 GlcNAc 2 -PP-Dol; Crithidia fasciculata, C.harmosa and Leishmania enriettii utilise biantennary Man 7 GlcNAc 2 -PP-Dol; Leishmania mexicana, Leishmania adleri and Blastocrithidia culicus utilise biantennary Man 6 GlcNAc 2 -PP-Dol (15) (16) (17) (18) . Trypanosma cruzi, the causative agent of Chagas' disease in the Americas, utilises Man 9 GlcNAc 2 -PP-Dol during most of its life-cycle but uses both Man 9 GlcNAc 2 -PP-Dol and Man 7 GlcNAc 2 -PP-Dol in its bloodstream trypomastigote stage (19) .
The insect-dwelling procyclic form of the African trypanosome T.brucei makes and transfers Man 9 GlcNAc 2 -PPDol (20) . Although bloodstream form T.brucei also makes Man 9 GlcNAc 2 -PP-Dol (21, 22) , it was demonstrated in pulsechase studies by Bangs et al that one of the two Nglycosylation sites of VSG variant ILTat1.3 receives an Endo H-resistant glycan in the ER (23) . This observation, together with the identification by Zamze et al (4) of unusually small (Man [3] [4] GlcNAc 2 ) N-glycans on mature VSG221 and the accumulation of substantial amounts of Man 5 GlcNAc 2 -PPDol in bloodstream form T.brucei (24) , suggests two possible models of protein N-glycosylation in the ER of bloodstream form T.brucei (23) : (a) The transfer of Man 9 GlcNAc 2 to some N-glycosylation sites and the transfer of (Endo H-resistant) Man 5 GlcNAc 2 to others. (b) The transfer of Man 9 GlcNAc 2 to both sites and the unusually rapid (immediate) processing of some sites to Endo H-resistant structures in the ER.
In order to help discriminate between these models and to gain further insights into protein N-glycosylation in this parasite, we constructed a bloodstream form T.brucei glucosidaseII null mutant, and used α-mannosidse inhibitors, and assessed their effects on VSG N-glycosylation patterns.
EXPERIMENTAL PROCEDURES
Cultivation of trypanosomes -Bloodstream form T.brucei genetically modified to express T7 polymerase and the tetracycline repressor protein were cultivated in HMI-9 medium containing 2.5 µg / ml G418 at 37 o C in a 5% CO 2 incubator as described in (25) . In some experiments, the parasites were grown for 48 h in the presence of 6 mM 1-deoxynojirimycin (Sigma), the α-glucosidase inhibitor, or with a cocktail of α-mannosidase inhibitors (186 µM kifunensin (Industrial Research Ltd., New Zealand), 100 µM swainsonine and 0.8 mM 1-deoxy-mannojirimycin (Toronto Reseaerch Chemicals, Canada)). Radiolabelling of trypanosomes and endoglycosidase digestions -Cells were washed and resuspended at 2.5 x 10 7 /ml in methionine-free DMEM medium, preincubated with or without 0.8 µg/ml tunicamycin (Calbiochem) for 15 min or with and without the aforementioned cocktail of α-mannosidase inhibitors for 30 min and pulse-labelled with 75 mCi /ml [ 35 S]-methionine (Amersham) for 3 min at 37 o C. Cells were cooled by addition of 20 ml ice-cold trypanosome dilution buffer (26) containing 1 mM methionine and harvested by centrifugation 800 x g for 10 min at 2 o C. The cell pellet was resuspended in 100 µl 0.5% SDS, 20 mM Tris-HCl pH 7.4 containing 1 mM phenylmethylsulfonylfluoride, 0.1 mM tosyl-lysylchloromethylketone, 1 mg/ml leupeptin, 1 mg/ml aprotinin, 0.1 M dithiothreitol and boiled for 10 min. Aliquots (5 µl) were combined with 20 µl 50 mM sodium citrate pH 5.5 containing 0.005 Units of Endo H (Roche) or with 20 µl sodium phosphate buffer pH 7.5, 1% NP-40 containing 500 Units PNGase F (New England Biolabs). Mock digestion controls were performed with buffer without enzyme. After 3 h at 37 o C, samples were mixed with an equal volume of 2 x concentrated SDS sample buffer, boiled and subjected to SDS-PAGE on a 10% gel. The gel was soaked in En 3 Hance (PerkinElmer) and exposed to Kodak XAR-5 film at -70 o C with a Dupont Cronex intensifying screen. DNA isolation and manipulation -Plasmid DNA was purified from E.coli (DH5α) using Qiagen Miniprep or Maxiprep kits, as appropriate. Gel extraction and reaction clean-up was performed using Qiaquick kits. Custom oligonucleotides were obtained from Thermo Hybaid or the Dundee University oligonucleotide facility. T. brucei genomic DNA was isolated from approximately 2 x 10 8 bloodstream form cells using DNAzol (Helena Biosciences), or from 5 x 10 9 procyclic cells using standard methods. Cloning and sequencing of the TbGlcaseIIα ORF -A 2517 bp region, including the 2421 bp ORF identified from the T.brucei genome database, was amplified from genomic DNA by PCR using Pfu DNA polymerase with 5'-tattgttgtttgcttgagtagg-3' and 5'-atgagcaacaagatcagacc-3' as forward and reverse primers, respectively. The cycling parameters used were 95 o C for five minutes, 35 cycles of 95 o C for 45 s, 58 o C for 45 s and 72 o C for 4 min followed by a final 10 min extension time at 72 o C. The products of three separate PCRs were ligated into the pCR-Blunt II-TOPO vector (Invitrogen) and one representative clone from each was used for triple pass DNA sequencing. Generation of gene replacement constructs -The 500-bp 5'-and 522-bp 3'-UTR sequences immediately adjacent to the start and stop codons of the TbGlcaseIIα ORF were PCR amplified from genomic DNA using Taq with 5'-tcaagtacGCGGCCGCtacgttgacggagcgacg-3' and 5'-tggacggtttaaacctaagcgaagcttcactgctagtttttcctactc-3' and 5'-cgcttaggtttaaaccgtccaggatccgatggcgaggccggcgggttg-3' and 5'-tcctcttaGCGGCCGCgacggcgtggaggaatgc-3' as forward and reverse primers, respectively. The two PCR products were used together in a further PCR reaction to yield a product containing the 5'-UTR linked to the 3'-UTR by a short HindIII, PmeI and BamHI cloning site (underlined) and NotI restriction sites at each end (capital letters). The product was cloned into the pCR4-TOPO vector (Invitrogen) by topoisomerase mediated ligation. Antibiotic resistance markers were cloned into the HindIII / BamHI restriction sites between the two UTRs to produce two constructs, one containing the puromycin acetyltransferase (PAC) drug resistance gene and one containing the hygromycin phosphotransferase (HPT) hygromycin drug resistance gene. Transformation of bloodstream form T. brucei -Constructs for gene replacement and ectopic expression were purified using the Qiagen Maxiprep kit, digested with NotI to linearise, precipitated and washed twice with 70% ethanol and redissolved in sterile water. The linearised DNA was electroporated into T. brucei bloodstream cells (strain 427, variant 221) that were stably transformed to express T7 RNA polymerase and the tetracycline repressor protein under G418 selection (25) . Cell culture and transformation was carried out as previously described (25, 27) . Southern blotting -Aliquots of genomic DNA isolated from 100 ml bloodstream form T. brucei cultures (approximately 2 x 10 8 cells) were digested with various restriction enzymes. Fluoroscein labelled probes were generated using the CDPstar random prime labelling kit (Gene Images); 250 ng template was used in a reaction volume of 50 µl and incubated for 90 min. Aliquots of 8 µl were used for each Southern blot experiment. Small scale VSG isolation -Soluble form VSG was isolated from 100 ml cultures, containing approximately 2 x10 8 bloodstream form T. brucei. The cultures were chilled on icewater and centrifuged at 2500 g for 10 min. The pellet was washed twice in trypanosome dilution buffer (26) and transferred to a 1.5 ml Eppendorf tube. The pellet was resuspended in 300 µl lysis buffer (10 mM NaH 2 PO 4 buffer pH 8.0, containing 0.1 mM TLCK, 1 µg / ml leupeptin and 1 µg / ml aprotinin) prewarmed to 37 o C and incubated for 5 min at the same temperature. The sample was centrifuged at 14,000g for 5 min and the supernatant applied to a 200 µl DE52 anion exchange column pre-equilibrated in lysis buffer. Fresh lysis buffer (800 µl without protease inhibitors) was applied in four stages and the pooled column eluate concentrated and diafiltered with water on a YM-10 spin concentrator (Microcon). The final sample of 50-100 µg sVSG221 was recovered in a volume of 100 µl water. ES-MS analysis of intact VSG -Samples of the small-scale VSG preparations were diluted to approximately 0.05 µg/µl in 50% acetonitrile, 1% formic acid or 50% methanol, 1% formic acid, loaded into nanotips (Micromass type F) and analysed by positive ion electrospray-mass spectrometry (ES-MS) on a QTof2 instrument (Micromass) with tip and cone voltages of 1 kV and 30 V, respectively, or an ABI Q-StarXL instrument with tip and declustering potentials of 900 V and 60 V, respectively. Data were collected, averaged and processed using the maximum entropy algorithm using MassLynx software or using the Bayesian protein reconstruction algorithm using ABI Analyst software. ES-MS/MS analysis of Pronase glycopeptides -Samples (50 µl) of the remaining VSG were mixed with 5 µl 1 M ammonium bicarbonate buffer and 10 µl of 10 mg/ml freshly prepared Pronase (Sigma) dissolved in 10 mM calcium acetate. After 48 h at 37 o C, the digest was acidified with 100 µl 1 M acetic acid, centrifuged in a microfuge and passed through a small column of 50 µl Chelex 100 (Na + ) over 100 µl Dowex AG50 (H + ). The column was eluted five times with 150 µl water and the combined eluates, containing the glycopetides, were dried by rotary evaporation. The samples were dissolved in 50 µl 30% propan-1-ol, 10% acetic acid or 50% methanol, 1% formic acid and aliquots were loaded into nanotips (Micromass type F) for mass spectrometry. Pronase glycopeptide fractions were analysed by positive ion ES-MS/MS in neutral loss scanning mode (neutral loss of m/z 81 for the loss of terminal hexose from doubly-charged parent ions) using a Micromass Ultima triple quadrupole mass spectrometer. Tip and cone voltages were 1 kV and 40 V and the collision energy was 15 V with argon as the collision gas at 3 x 10 -3 Torr. Glycopeptide ions identified in this experiment were analysed on a QTof2 instrument (using the same source conditions) or on a Q-StarXL instrument, with tip and declustering potentials of 900 V and 60V, in product ion scanning mode using collision energies of 30-60 V. Large scale VSG and VSG N-glycan isolationTbGlcaseIIα -/-null mutant parasites (2 x 10 11 ) were harvested from the infected blood of 20 rats as previously described (27) . The parasites were lysed by osmotic shock and the sVSG released into the supernatant purified using DE-52 anion exchange chromatography according to the method of Cross (28). The VSG was further purified by gel filtration on a 850 x 2.5 cm Sephacryl S200 column eluted with 100 mm ammonium bicarbonate at 10 ml/h (29) . The protein peak fractions were pooled to yield 36 mg sVSG following dialysis against water and lyophilisation. A sample of sVSG221 (25 mg) was incubated in 200 µl 0.5% SDS, 1% β-mercaptoethanol (100 o C, 30 min), cooled and diluted with 800 µl 125 mM sodium phosphate buffer (pH 7.0), 0.625% Triton-X100, 25 mM EDTA, 1% β-mercaptoethanol. The denatured glycoprotein was then treated with 50 U PNGase F (Roche) for 16 h at 37 o C. The PNGase-F digest was made 75 % with respect to ice-cold ethanol and incubated at -20 o C overnight to precipitate the bulk of the protein. After centrifugation, the supernatant was dried and dissolved in 100 mM ammonium bicarbonate for gel filtration on a Sephacryl S200 column (13 x 1.5 cm) eluted a 10 ml/h. Fractions of 1 ml were collected and 10 µl aliquots spotted onto a silica gel-60 TLC plate (Merck) and stained for carbohydrate with orcinol reagent. The carbohydrate-positive fractions, containing the released Nglycans, were recovered close to the included volume, well separated from a major A280 absorption peak containing protein and detergent micelles. The glycan-containing fractions were pooled, lyophilised and desalted by passage through 0.2 ml Chelex 100 (Na + ) over 0.5 ml Dowex AG50 (H + ) over 0.5 ml Dowex AG3 (OH -) over 0.2 ml QAESephadex A25 (OH -). The eluate and four column washings with 1.4 ml water were pooled, dried by rotary evaporation and dissolved in a 100 µl water. N-glycan fractionation -The N-glycan pool released from sVSG221 was separated by Dionex HPAEC on a 4.6 x 250 mm Carbopack PA1 column eluted at 0.6 ml/min with 5 mM sodium acetate in 0.1 M NaOH for 5 min followed by a linear gradient to 150 mM sodium acetate in 0.1 M NaOH over 55 min. Sodium ions were removed from the eluate on-line with a Dionex ARRS unit. Aliquots (1%) of each 0.3 ml fraction were applied to a silicagel-60 TLC plate and stained with orcinol. Carbohydrate-positive fractions were identified eluting between 30.5 and 36.0 min. Aliquots of these fractions (3 µl 
Permethylation and ES-MS/MS of N-glycans -Samples
recovered from NMR were exchanged back into H 2 O by passage through a short column (20 x 1 cm) of BioGel P2 (BioRad) equilibrated and eluted with water. Samples were dried and permethylated by the sodium hydroxide method, as described in (30) . The permethylated glycans were dissolved in 100 µl 80% acetonitrile and aliquots (2 µl) were mixed with an equal volume of 80% acetonitrile, 1 mM sodium acetate prior to loading into nanotips (Micromass type F) for positive ion ES-MS and ES-MS/MS on a QTof2 mass spectrometer (Micromass, U.K.). Tip and cone voltages were 1 kV and 40 V, respectively, and the collision energy was 45-70 V.
Methylation linkage analysis by GC-MS -
The remainder of the permethylated glycan samples were subjected to acid hydrolysis, NaB 2 H 4 -reduction and acetylation (to yield partially methylated alditol acetates, PMAAs) and analysed by GC-MS as described in (30) . The PMAAs were analysed on an Agilent HP-5 column and on a Supelco SP2380 column (the latter to allow resolution of the non-reducing terminalMan and non-reducing terminal-Glc PMAAs). Tritium labelling and HPTLC analysis of glycans -Samples of pools B, C and D (2 nmol each) were dried and reduced with 5 µl 5.5 mM NaB 3 H 4 in 16.6. mM NaOH (16 h, 22 o C). Excess reductant was added (5 µl 0.5 M NaB 3 H 4 ) and the incubation continued for 3 h. The samples were acidified with 10 µl 1 M acetic acid in a fume hood, passed through 0.2 ml Dowex AG50 (H + ) and dried. Boric acid was removed by coevaporation with 2 x 250 µl 5% acetic acid in methanol and 2 x 250 µl methanol. The labelled glycans were dissolved in water and applied to 3 cm-wide strips of Whatman 3MM paper for downward paper chromatography in butan-1-ol, ethanol, water (4:1:0.8). Labelled glycans were recovered from the origin by elution with water and desalted by passage through a column of 100 µl each Chelex 100 (Na 
. The column was eluted four times with 400 µl water and the combined eluates were dried by rotary evaporation. The 3 H-labelled glycans were then purified by Dionex HPAEC, as described above. The same strategy was used to generate highly purified labelled standards of Man 6 GlcNAc 2 (i.e., Manα1-6(Manα1-
3 H]GlcNAc-ol. The unlabelled Man 6 GlcNAc 2 and NA2 glycans were obtained from (Dextra Labs, U.K.). The Thy-1 GPI standard (i.e., Manα1-2Manα1-6(GalNAcβ1-4)Manα1-4 [1- 3 H]2,5-anhydromannitol) was prepared from rat brain Thy1 glycoprotein, as described in (31) .
Aliquots equivalent to 10,000 cpm (before and after digestion with jack bean α-mannosidase (Calbiochem) and E.coli β1-4 galactosidase (Roche) or partial acetolysis (32)) were applied to a 10 cm aluminium backed silicagel-60 HPTLC plate (Merck) and developed with butan-1-ol : ethanol : water (4 : 3 : 3 v/v/v) three times (32) . Radiolabelled components were detected by fluorography at -70 o C after spraying with En 3 Hance (PerkinElmer) using Kodak X-OMAT AR film and an intensifying screen. These results show that newly synthesised (ER-resident) VSG221 contains one conventional Endo H-sensitive Nglycan and one Endo H-resistant N-glycan. This reproduces the observation made for a similar doubly-N-glycosylated VSG (variant ILtat1.3) (23) and shows that bloodstream form T.brucei cells exhibit both a conventional and aberrant features of protein N-glycosylation. Thus, whereas in other eukaryotes all N-glycans are Endo H sensitive until glycoproteins are processed in the Golgi apparatus (several minutes after synthesis in the ER), in T.brucei some Nglycans are Endo H resistant upon or immediately after transfer to VSG polypeptide in the ER. Bioinformatic analysis -Local alignment searching (tBLASTn) (33) of T. brucei genome data held in GeneDB at The Sanger Institute with yeast and/or mouse genes associated with the biosynthesis of Dol-PP-oligosaccharide donors, their transfer to Asn-X-Ser/Thr sequons and subsequent ER processing was performed (Table I ). The search using the mouse glucosidase II alpha subunit as a query sequence identified two putative open reading frames showing significant sequence similarity (62% and 51%). The homologue with the greatest similarity to the query (gene number Tb10.05.0080) was chosen for further analysis and was later demonstrated to be the T. brucei glucosidase II alpha subunit (TbGlcaseIIα). The second homologue (gene number Tb11.01.2140) showed greater similarity to human lysosomal alpha glucosidase and was not studied further. A putative homologue of the human glucosidase II β-subunit was also found ( Table I ), suggesting that the T. brucei contains a conventional α/β glucosidase II assembly in the ER, although the T.brucei β-subunit homologue lacks an identifiable ER retention sequence. Homologues of UDP-Glc:glycoprotein glucosyltransferase (UGGT) and calreticulin (CRT) were also found (Table I) . However, like in Trypanosoma cruzi (34) , no calnexin (CNX) homologue was apparent, these data suggests that T.brucei has a relatively conventional eukaryotic calreticulin-mediated glycoprotein refolding quality control system (7, 10, 11) . On the other hand, BLAST searches for homologues of eukaryotic genes involved in the biosynthesis of the conventional Glc 3 Man 9 GlcNAc 2 -PP-Dol N-glycan precursor indicated that the ALG6, 8 and 10 genes (encoding the three Dol-P-Glc-dependant α-glucosyltransferases) were absent as were obvious homologues for Dol-P-Glc synthetase (ALG5) and glucosidase I (Table I) . Similar conclusions were reported recently by Samuelson et al (35) .
RESULTS

Endo
Cloning and Sequencing of the TbGlcaseIIα ORF -The
TbGlcaseIIα ORF was amplified from T.brucei genomic DNA by PCR using Pfu polymerase. Three clones from separate amplifications were sequenced three times each. The consensus sequence (accession number AJ865333) revealed eleven base differences compared to the genome database assembly (gene number Tb10.05.0080). All of the differences were silent with respect to predicted amino acid sequence and probably represent differences between the strain used for the genome sequencing project (TREU927/4) and that used in this study (strain 427). The amino acid sequence suggests that TbGlcaseIIα encodes a glycosyl hydorolase family 31 protein with a cleavable N-terminal signal peptide for import into the ER (residues 1-19) and two potential N-glycosylation sites at Asn122 and Asn736. Generation of TbGlcaseIIα null and conditional null mutant cell lines -Strain 427 bloodstream form T.brucei parasites expressing VSG221 and transformed to stably express T7 polymerase and the tetracycline repressor protein under G418 antibiotic selection were used in this study (25) and are referred to here as 'wild type'. Southern blot analysis using a TbGlcaseIIa ORF probe suggested that TbGlcaseIIa is a single copy gene per haploid genome (data not shown). The genetic modifications described below are summarised in (Fig. 2A) . Linear DNA, containing approximately 500 bp each of TbGlcaseIIa 5'-UTR and 3'-UTR, surrounding a hygromycin phosphotransferase (HPT) gene, was introduced into bloodstream form T.brucei parasites by electroporation. Clones in which one allele of TbGlcaseIIα was replaced by HPT by homologous recombination (ΔTbGlcaseIIα::HPT) were selected with hygromycin. The second TbGlcaseII allele was replaced in a ΔTbGlcaseIIα::HPT clone in the same way with puromycin acetyltransferase (PAC). Hygromycin and puromycin resistant clones (ΔTbGlcaseIIα::HPT / ΔTbGlcaseIIα::PAC null mutants) were selected. Southern blot analysis of the wild-type, ΔTbGlcaseIIα::HPT and ΔTbGlcaseIIα::HPT / ΔTbGlcaseIIα::PAC null mutant cells with a probe to the TbGlcaseIIα 5'-UTR confirmed that both alleles had been replaced (Fig. 2B) . The null mutant cell line had no noticeable differences in gross morphology. However, it exhibited marginally slower growth in culture (doubling time 6.4±0.5 h) than the parental cell line (doubling time 5.5±0.5 h).
A tetracycline-inducible ectopic copy of the TbGlcaseIIα gene was introduced into a null mutant clone using the pLew82 vector (25) 8 cells from 100 ml of culture were processed to yield 50-100 µg of purified sVSG221. Aliquots were analysed by positive ion ES-MS. The deconvoluted mass spectra of the intact glycoproteins are shown in (Fig 3) . The wild type profile (Fig. 3A) shows the range of different glycoforms that arise from known heterogeneity in the GPI anchor (36) and N-glycan sites (4) ( Table II) . VSG from the TbGlcaseIIα null mutant showed a significant difference in glycoform pattern with a shift of glycoforms to higher mass equivalent to approximately three hexose units (486 Da) (Fig. 3B ). This change in glycoform pattern was reversed in the tetracycline-induced conditional null ('add-back') mutant (Fig. 3C) , demonstrating that the change in VSG glycoform profile was a direct result of TbGlcaseIIα gene deletion. An identical change in VSG glycoforms to that seen in the null mutant was observed when wild type cells were grown for 48 h in the presence of 6 mM 1-deoxynojirimycin, a broad specificity α-glucosidase inhibitor (37), prior to VSG isolation (Fig. 3D) . The latter result suggests that the TbGlcaseIIα gene analysed in this study is the only ER α-glucosidase involved in N-glycan processing in T.brucei. Characterisation of VSG Pronase glycopeptides from wild type and TbGlcaseIIα null mutant cell lines -To probe the nature of the changes in VSG glycosylation induced by deletion of the TbGlcaseIIα gene, aliquots of wild-type and null mutant VSG samples (approximately 50 µg) were digested with Pronase and analysed by ES-MS/MS in neutral loss scanning mode. This method filters the spectrum for doubly-charged glycopeptide ions that can lose a terminal hexose residue (m/z 81) when they undergo collision induced dissociation ( Fig. 4A and B) . These data showed no apparent changes in the masses of the GPIpeptide fragments or the C-terminal (Asn428) Hex 9-7 HexNAc 2 -containing glycopeptides. The identities of these ions were confirmed by daughter ion ES-MS/MS on a QTof2 mass spectrometer; eg. (Fig. 4C and D) .
The absence of any hint of Hex 10 GlcNAc 2 -NT/NTT ions in (Fig. 4B) is noteworthy. This suggests that deletion of the TbGlcaseIIα gene does not lead to any Glc 1 Man 9 GlcNAc 2 structures attached to the C-terminal Asn486 site. On the other hand, the internal (Asn263) glycopeptides were changed from the previously characterised Hex 3 HexNac 2 -, Hex 3 HexHAc 3 -and Hex 4 HexNAc 3 -containing species (4) to Hex 6 HexNAc 2 -containing species (Fig 4B) . The identities of these ions were confirmed by daughter ion ES-MS/MS on a QTof2 mass spectrometer; eg. (Fig. 4E and F) . In order to characterise these changes, N-linked glycans were isolated from the null mutant VSG for detailed structural analysis. (4) . Notably, there was no evidence for the presence of a terminal glucose residue in these structures (that would otherwise give rise to a B-type daughter ion at m/z 853 corresponding to a linear Hex4 branch; see below). To confirm this, aliquots of the native glycans were radiolabelled by reduction in NaB 3 H 4 and analysed along with radiolabelled oligomannose standards by HPTLC with and without treatment with jack bean α-mannosidase (JBAM). Both structures were fully digested to Manβ1-4GlcNAcβ1-4GlcNAc-ol, confirming the lack of any JBAM-resistant αGlc residues in the parent structures (data not shown).
The novel Hex 6 HexNAc 2 structure from the Asn263 site was analysed by GC-MS compositional analysis, 1-D and 2-D 1 H-NMR and, following permethylation, ES-MS/MS and GC-MS methylation linkage analysis.
The 1-D NMR spectrum revealed eight well-resolved anomeric protons. The chemical shift and J 1,2 coupling constant values suggested the presence of an αGlc residue, four αMan residues, a βMan residue and two βGlcNAc residues (38) (Fig. 5A ). These assignments were confirmed when intra-residue connectivity networks were traced from COSY, ROESY and TOCSY spectra, which allowed assignment of additional protons in each spin-system (Table  III) . Using the residue descriptors shown in (Fig. 5A) , interresidue connectivities were observed in the ROESY spectrum between G3-H1and D1-H3, D1-H1 and C-H2, C-H1 and 4-H2 (Fig. 5B) . This suggests the linear sequence Glcα1-3Manα1-2Manα1-2Manα1-. These assignments were consistent with the ES-MS/MS data that show a linear Hex 4 branch, indicated by the m/z 853 B-type and m/z 953 Y-type daughter ions (Fig. 6A) . The GC-MS methylation linkage analysis showed the presence of a terminal Glc residue together with terminal Man, 3-O-substitiuted Man, 2-Osubsitituted Man and 3,6-di-O-substituted Man residues (Table IV) . To assess whether the Glcα1-3Manα1-2Manα1-2Man branch was attached to the 3-or the 6-position of the βMan residue of the Manβ1-4GlcNAcβ1-4GlcNAc unit, the NaB 3 H 4 -reduced oligosaccharide was analysed by HPTLC before and after partial acetolysis. This treatment, which is selective for the cleavage of Manα1-6Man glycosidic bonds, resulted in the loss of one hexose residue (Fig. 7A, lanes 1  and 2) , consistent with a single αMan attached to the 6-position and the Glcα1-3Manα1-2Manα1-2Man branch attached to the 3-position (Fig. 7C) . Taken together, these data provide support for the structure proposed in (Fig. 5A) . This structure contains a conventional biantennary Manα1-3(Manα1-6)Manβ1-4GlcNAcβ1-4GlcNAc core that is extended on the 3-arm as follows: Glcα1-3Manα1-2Manα1-2Manα1-3(Manα1-6)Manβ1-4GlcNAcβ1-4GlcNAc. The likely origin of this structure is discussed later.
Similar analyses of the Hex 6 HexNAc 3 structure showed that this material had an additional terminal βGlcNAc residue on the 6-arm of the Manα1-3(Manα1-6)Manβ1-4GlcNAcβ1-4GlcNAc core. Thus, the NMR data are similar to those for the Hex 6 HexNAc 2 except for the presence of an additional βGlcNAc residue, residue 5' (Fig.  5C) (Fig. 7B) . Methylation linkage analysis (Table IV) (Fig. 7A, lanes 3 and 4) , supporting the notion that the additional βGlcNAc residue is attached to the 4' residue (Fig. 7C) . Taken together, these data provide support for the structure proposed in (Fig. 5C ). This structure contains a conventional biantennary Manα1-3(Manα1-6)Manβ1-4GlcNAcβ1-4GlcNAc core that extended on the 3-arm and the 6-arm as follows: Glcα1-3Manα1-2Manα1-2Manα1-3(GlcNAcβ1-2Manα1-6)Manβ1-4GlcNAcβ1-4GlcNAc.
There was insufficient Hex 7 HexNAc 3 material for NMR and methylation linkage analysis. However, the m/z 853 Btype daughter ion in the ES-MS/MS spectrum clearly indicates the presence of the linear Hex 4 branch, together with a terminal Hex-HexNAc unit (indicated by the intense m/z 486 B-type daughter ion) (Fig. 6C ). This new terminal Hex residue was deduced to be a βGal residue in 1-4 linkage to the underlying GlcNAc residue by digestion of the NaB 3 H 4 -reduced Hex 7 HexNAc 3 oligosaccharide with E.coli β1-4-specific β-galactosidase (Fig. 7B , lanes 5 and 6). As expected, neither the Hex 6 HexNAc 2 nor the Hex 6 HexNAc 3 were digested by β-galactosidase (Fig. 7B,  lanes 1-4) . The location of the Galβ1-4GlcNAc unit was inferred by partial acetolysis of the NaB 3 H 4 -reduced Hex 7 HexNAc 3 oligosaccharide. Thus, the terminal product of this reaction was also Hex 5 HexNAc 2 (Fig. 7A , lanes 5 and 6), suggesting that it is attached to the 4' residue (Fig.  7C) . These data are consistent with the structure: Glcα1-3Manα1-2Manα1-2Manα1-3(Galβ1-4GlcNAcβ1-2Manα1-6)Manβ1-4GlcNAcβ1-4GlcNAc. The effects of α-mannosidase inhibitors on wild-type VSG221 N-glycosylation -The novel structures found at the Asn263 glycosylation site in the glucosidase II null mutant point to the transfer of Man 5 GlcNAc 2 , its subsequent glucosylation by UGGT and processing by GlcNAc-and Gal-transferases. However, it is also conceivable that trypanosomes might perform unusually rapid α-mannosidase trimming of a conventional Man 9 GlcNAc 2 structure to Man 5 GlcNAc 2 at that site.
To address this possibility, we repeated the experiment shown in (Fig. 1) after pre-incubation with a cocktail of cell-permeable α-mannosidase inhibitors (186 µM kifunensin, 100 µM swainsonine and 0.8 mM 1-deoxymannojirimycin). The results (Fig. 8A) are very similar to those in (Fig. 1); i.e., after a 3 min pulse-label one of the 2 N-glycosylation sites is already endo H resistant, suggesting that Asn263 is not rapidly processed by α-mannosidases from endo H-sensitive Man 9 GlcNAc 2 to endo H-resistant Man 5 GlcNAc 2 . To confirm this, we grew wild-type trypanosomes for 48 h in the presence and absence of the α-mannosidase inhibitor cocktail and assessed the effects of the inhibitors on VSG221 Nglycosylation by mass spectrometry. Aliquots of purified VSG221 were analysed by positive ion ES-MS and the mass spectra of the intact glycoproteins are shown in (Fig 8B and  C) . The wild type profile (Fig. 8B) shows the range of different glycoforms that arise from known heterogeneity in the GPI anchor (37) and N-glycan sites (4) ( Table II) . VSG from the mannosidase inhibitor-treated cells showed a significant difference in glycoform pattern, with a shift of glycoforms to higher mass (Fig. 8C) and (Table II) . These data indicate that the mannosidase inhibitor cocktail is active. To assess the effects of the mannosidase inhibitors on the individual N-glycosylation sites, aliquots of wild-type and mannosidase inhibitor-treated VSG samples were digested with Pronase and analysed by ES-MS/MS in neutral loss scanning mode, as described earlier. These data showed no apparent changes in the masses of the GPI-peptide fragments but, as expected, a significant reduction in the α-mannosidase-mediated processing of Man 9 GlcNA 2 to Man 8 GlcNA 2 and Man 7 GlcNA 2 at the C-terminal Asn428 glycosylation site, compare ( Fig. 8D) with (Fig. 8E) . The glycans at the internal Asn263 site were 2 hexose units larger in the α-mannosidase-treated sample than the wild typesample, compare ( Fig. 8D) with (Fig. 8E) . This is consistent with inhibition of the α-mannosidases responsible for trimming the 3-arm of the biantennary Man 5 GlcNAc 2 to Man 3 GlcNAc 2 but inconsistent with the rapid α-mannosidase processing of a conventional Man 9 GlcNAc 2 precursor at this glycosylation site.
Based on the data of Zamze et al (4) and this paper, the differences in VSG221 glycosylation between wild-type, TbGlcaseIIα null mutant trypanosomes and α-mannosidase inhibitor-treated wild type trypanosomes are summarised in (Fig. 9) .
DISCUSSION
It is clear that, despite slightly retarded growth in the null mutant, TbGlcaseIIα is a non-essential enzyme for the growth of bloodstream form T.brucei in vitro and in vivo. We were also able to successfully differentiate the null mutant into procyclic form T.brucei in vitro (data not shown), suggesting that the gene is also not required for differentiation to, or survival of, the procyclic form of the parasite. In this regard, our results are similar to those of Parodi and colleagues, who have shown that, in the related American parasite T.cruzi, other components of the ER glucosylation-dependent quality control system (i.e., calreticulin and UGGT) can be deleted with only moderate effects on parasite growth, differentiation and infectivity (34, 39) . However, analysis of the biochemical phenotype of the T.brucei glucosidase II null mutant, together with BLAST searches for glycosylation gene homologues, has helped to reveal and explain some of the idiosyncrasies of protein N-glycosylation in the African trypanosome, summarised in (Fig. 10) .
While the T.brucei genome contains homologues of Dol-P-Man synthase and all of the known components needed to synthesise Man 5 GlcNAc 2 -PP-Dol, to flip this species into the lumen of the ER and to assemble Man 9 GlcNAc 2 -PP-Dol, trypanosome equivalents of the three Dol-P-Glcdependent α-glucosyltransferases (encoded by ALG6, ALG8 and ALG10 in yeast) and Dol-P-Glc synthase (ALG5) are absent (Table I) and (35) . This is in agreement with published data that show that the largest Dol-PPoligosaccharide species observed in both bloodstream form and procyclic form T.brucei is Man 9 GlcNAc 2 -PP-Dol (20) (21) (22) and not the Glc 3 Man 9 GlcNAc 2 -PP-Dol species common to most other eukaryotes (7, 10, 11) . Perhaps unsurprisingly, a homologue of glucosidase I (that removes the terminal αGlc residue from Glc 3 Man 9 GlcNAc 2 -protein) is also absent from the genome. On the other hand, there appears to be components of a calreticulin-(but not clanexin-) mediated glycoprotein refolding quality control system, including homologues of UGGT and α-and β-subunits of glucosidase II. The null mutant generated in this study confirms the biochemical activity of glucosidase II, since in its absence half of the N-linked glycans of VSG are expressed bearing terminal αGlc residues on their 3-arms. This also infers that the UGGT homologue is expressed in bloodstream form T.brucei and is enzymatically active. The transfer of Man 9 GlcNAc 2 to both sites and the unusually rapid (immediate) processing of some sites to Endo H-resistant structures in the ER. We reasoned, based on the specificity of UGGT for Man 9-7 GlcNAc 2 linked to unfolded protein in other organisms (13) , that deletion of the T.brucei glucosidaseII would 'lock' protein-linked Man 9 GlcNAc 2 structures in a glucosylated form 2 and allow us to discriminate between these two models. Thus, we expected to find either, according to model (a), Glc 1 Man 9-7 GlcNAc 2 at the Asn428 site of VSG221 and unchanged small Endo H-resistant structures at the Asn263 site or, according to model (b), Glc 1 Man 9-7 GlcNAc 2 at both sites. However, analysis of the oligosaccharide structures attached to the two Nglycosylation sites of VSG221 in the null mutant revealed unexpected features. Thus, the C-terminal Asn428 Nglycosylation site was unchanged (carrying predominantly Man 9 GlcNAc 2 and Man 8 GlcNAc 2 chains) whereas the internal Asn263 site now expressed larger structures due to the presence of an extended (αGlc-capped) 3-arm (Fig. 9) . These results are counterintuitive since the preferred substrate for rat glucosidase II is Glc 1 Man 9 GlcNAc 2 , with by guest on November 15, 2017 http://www.jbc.org/ Downloaded from Glc 1 Man 5 GlcNAc 2 being a particularly poor substrate (40) . Furthermore, the results suggest that T.brucei UGGT glucosylates Man 5 GlcNAc 2 , and not Man 9 GlcNAc 2 , on VSG whereas UGGT from other organisms has been reported to have a marked preference for Man 9-7 GlcNAc 2 over Man 5 GlcNAc 2 (13) . These unexpected results prompted us to re-evaluate our assumptions, based on examples from mammalian cells (41) , that Man 9 GlcNAc 2 structures attached to protein in the ER of the parasite could not be processed by ER mannosidases to anything other than triantennary endo Hsensitive Man 5 GlcNAc 2 structures. Consequently, we analysed the effects of a cocktail of three potent cellpermeable α-mannosidase inhibitors (kifunensin, swainsonine and 1-deoxymannojirimycin), which between them can inhibit all known classes of ER and Golgi α-mannosidases, on the processing of wild-type VSG221 N-glycans. In these experiments (Fig. 8) , the inhibitors were clearly active but the results were consistent with model (a), above.
Thus, we postulate that T.brucei uses two types of dolichollinked oligosaccharide for transfer to VSG in the ER (Fig.  10) ; a conventional triantennary Man 9 GlcNAc 2 -PP-Dol for transfer to sites destined to remain oligomannose (Man 9 GlcNAc 2 to Man 5 GlcNAc 2 ) and a biantennary Endo Hresistant Man 5 GlcNAc 2 -PP-Dol for transfer to sites destined to be directly involved in calreticulin-mediated protein folding and ultimately to be processed down to Man 3 GlcNAc 2 and thence to complex structures. The fact that this organism uses these mechanisms on different sites of the same glycoprotein suggests that either the different VSG glycosylation sites somehow recruit different Dol-PPoligosaccharde donors to the same ER translocon/OST complex or that one or both sites are glycosylated after protein translocation into the ER. In the latter model, the different VSG glycosylation sites might then recruit OST complexes with different donor specificities. The fact that post-translational N-glycosylation has been observed for some VSG variants (23, 42) provides tentative support for the latter model.
While it has been shown that other eukaryotes will transfer structures other than Glc 3 Man 9 GlcNAc 2 to protein (eg. many other trypanosomatids transfer Man 9 GlcNAc 2 , Man 7 GlcNAc 2 or Man 6 GlcNAc 2 (14) and the protozoan Tetrahymena pyriformis (43) and glucose-starved baby hamster kidney cells (44) transfer Glc 3 Man 5 GlcNAc 2 ) this is, to our knowledge, only the second example (after T.cruzi bloodstream trypomastigotes (14, 19) ) of a an organism utilising more than one Dol-PP-oligosaccharide donor under normal growth conditions and the first example of sitespecific N-glycosylation in a single glycoprotein.
In T.brucei, the requirement for such a dual system of protein N-glycosylation may stem from the requirements for rapid of VSG synthesis (10 million copies must be made for each cell division). Thus, once the trypanosomatids lost the strict requirement for glucosylated Dol-PP-oligosacchrides for efficient transfer to protein by OST, they would have also lost the requirement to process down from Man 9 GlcNAc 2 to Man 3 GlcNAc 2 prior to adding additional sugars. Since, according to precedent (7, 10, 11) , the smallest Dol-PPoligosaccharide to appear in the lumen of the ER is likely to be biantennary Man 5 GlcNAc 2 -PP-Dol it makes metabolic sense that T.brucei should immediately attach this structure to those N-glycosylation sites destined for processing to Man 4 GlcNAc 2 , Man 3 GlcNAc 2 and conventional Man 3 GlcNAc 2 -based complex structures. Indeed, such a mechanism still allows the transfer and processing of Man 9 GlcNAc 2 to conventional (Man 9-5 GlcNAc 2 ) oligomannose structures where these are required but minimises the drain on Dol-P-Man donors (necessary for converting Man 5 GlcNAc 2 to Man 9 GlcNAc 2 ) that are also required for GPI anchor biosynthesis. The latter is prodigious in these organisms because they appear to make >10-fold excess of GPI precursors over their requirement for VSG anchorage (45).
Finally, it is worth noting that analysis of the VSG of the TbGlcaseIIα null mutant has also revealed significant differences between the parasite and higher eukaryotes in N-glycan processing to complex structures. Whereas in higher eukaryotes the addition of β1-2 linked GlcNAc residues via GnT-I and GnT-II to the 3-and 6-arms, respectively, of the Man 3 GlcNAc 2 core occurs by GnT-I action on the triantennary acceptor substrate Man 5 GlcNAc 2 , followed removal of two αMan residues and the action of GnT-II on the GlcNAcβ1-2Manα1-3(Manα1-6)Manβ1-4GlcNAcβ1-4GlcNAc product (46), this sequence of events does not occur in T.brucei. For example, in the TbGlcaseIIα null mutant it is evident that biantennary Glc 1 Man 5 GlcNAc 2 can act as a substrate for TbGnT-II (and subsequently for β1-4Gal-T) on the 6-arm. Also, since wild type trypanosomes normally process the glycan at Asn263 up to a conventional biantennary complex structure (Fig.  9 ), it appears that the substrate for TbGnT-I is Man 3 GlcNAc 2 and not triantennary Man 5 GlcNAc 2 . We may, therefore, conclude that the GlcNAc-transferases involved in making complex N-glycans in T.brucei are different from their mammalian counterparts. Indeed, BLAST searches for homologues of the mammalian enzymes fail to return obvious parasite homologues. Such differences in amino acid sequence and substrate specificity point to host/parasite differences in N-glycan processing enzymes that may be exploitable.
In summary, the results presented here support the conclusions that: (i) Bloodstream form T.brucei can transfer both Man 9 GlcNAc 2 and Man 5 GlcNAc 2 to VSG in a site-specific manner. (ii) Unlike organisms that transfer exclusively Glc 3 Man 9 GlcNAc 2 , the T.brucei UGGT and gucosidase II enzymes appear to prefer Man 5 GlcNAc 2 Glc 1 Man 5 GlcNAc 2 , respectively, as their substrates (though data from more glycoprotein glycosylation sites is needed to test this hypothesis). (iii) The ability to transfer Man 5 GlcNAc 2 structures to N-glycosylation sites destined to become Man 4-3 GlcNAc 2 or complex structures may have evolved as a mechanism to conserve Dol-P-Man donors for GPI anchor biosynthesis in this organism. (iv) There are fundamental differences in the acceptor substrate specificities of host and parasite GlcNAc-transferases that initiate the synthesis of complex N-glycans. (Table III) . 2+ permethylated Hex 7 HexNAc 3 ion. All spectra were processed (using the MassLynx maximum entropy 3 algorithm) to produce spectra consisting only of singly-charged ions. Labelled glycans were analysed before (-) and after (+) digestion with E.coli β1-4 galactosidase. The interpretation of the product of the digestion of Hex 7 HexNAc 3 is shown inside the dotted box in (panel C). The control biantennary glycan (NA2) lost two terminal βGal residues, as expected (lanes 9 and 10). The control Thy-1 GPI glycan was unaffected by β-galactosidase digestion (lanes 11 and 12) , showing that the enzyme was not contaminated with α-mannosidase or β-N-acetylhexosaminidase activities. The molecular weights of different glycoforms of sVSG221 were calculated according to the indicated compositions. The -, tr, +, ++, and +++ scores indicate the relative abundances of those glycoforms observed in (Fig. 3) NET [M+H+Na] NE [M+H+Na] 1100.20 
